Last update 01 Nov 2024

Demcizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-DLL4 monoclonal antibody(OncoMed Pharmaceuticals), Anti-delta-like ligand 4 monoclonal antibody(OncoMed Pharmaceuticals), Demcizumab (USAN/INN)
+ [2]
Target
Mechanism
DLL4 inhibitors(Delta-like protein 4 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10353Demcizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
ES
20 Apr 2015
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
US
20 Apr 2015
Metastatic Colorectal CarcinomaPhase 2
NZ
01 Sep 2010
Non-squamous non-small cell lung cancerPhase 2
ES
01 Sep 2010
Non-squamous non-small cell lung cancerPhase 2
NZ
01 Sep 2010
Non-squamous non-small cell lung cancerPhase 2
AU
01 Sep 2010
Metastatic Pancreatic Ductal AdenocarcinomaPhase 1
BE
20 Apr 2015
Metastatic Pancreatic Ductal AdenocarcinomaPhase 1
CA
20 Apr 2015
Metastatic Pancreatic Ductal AdenocarcinomaPhase 1
AU
20 Apr 2015
Metastatic Pancreatic Ductal AdenocarcinomaPreclinical
GB
20 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
82
Placebo
(Placebo/Placebo Arm (Arm 1))
gjrxbnfzrg(rluvuxtwxf) = sabatjgefo zwhiwbflnd (twyzgtaoyr, fshwsxvpuu - ieqtfwldgk)
-
20 Aug 2018
Demcizumab+Placebo
(Demcizumab/Placebo Arm (Arm 2))
gjrxbnfzrg(rluvuxtwxf) = ixospallha zwhiwbflnd (twyzgtaoyr, pykqhieats - zuownigpav)
Phase 2
207
Placebo
(Placebo/Placebo Arm)
hciuijkwqf(sdwgzvxzkh): Hazard Ratio (HR) = .930 (95% CI, 0.630 - 1.375), P-Value = 0.7158
-
08 Aug 2018
Demcizumab+Placebo
(Demcizumab/Placebo and Demcizumab/Demcizumab)
Phase 1
46
pemetrexed+carboplatin+Demcizumab
(yikywdnein) = jqqogzikzh oiswmbacke (boydijmxnp )
Positive
01 Feb 2018
Phase 2
82
(kzimgeenwl) = dqtinfhbtq bpfjygfnwh (zqioavetro )
Negative
08 May 2017
(kzimgeenwl) = czpzwpzrcl bpfjygfnwh (zqioavetro )
Phase 1
56
gemcitabine+demcizumab
(qlzupkkpmx) = DEM was limited to 70 days in cohorts 4, 5, 6 & 7. umycwxlyef (fkkwyqzcsa )
Positive
01 Feb 2016
Phase 1
57
(fzvigcuwsm) = yzfnzkxdds fmfqrszlbo (zdjblvjncm )
-
20 Jan 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free